Sampling Strategies for Chart Review Studies

Published on 22/12/2025

How to Design Effective Sampling Strategies for Retrospective Chart Review Studies

Retrospective chart reviews are instrumental in generating real-world evidence (RWE) from historical patient data. One critical component of designing these studies is selecting an appropriate sampling strategy. A poorly chosen sample can lead to bias, threaten validity, and limit generalizability. In this tutorial, we’ll guide pharma professionals and clinical trial teams through the best practices for developing rigorous sampling strategies tailored to retrospective chart review studies.

Table of Contents

Why Sampling Matters in Retrospective Research

Retrospective chart reviews typically involve large databases, such as electronic health records (EHRs) or archived paper files. Reviewing every case is often impractical and unnecessary. Instead, a representative sample provides sufficient statistical power while reducing cost and workload. A well-planned sampling strategy:

Improves external validity and reduces bias
Ensures consistency across study sites
Supports regulatory compliance and reproducibility
Enhances audit-readiness and aligns with GMP compliance practices

Step 1: Define the Target Population

Before selecting a sample, clearly define your study population based on inclusion and exclusion criteria. These may include:

Diagnosis codes (e.g., ICD-10)
Age, gender, or demographic characteristics
Treatment received or medication use
Geographic or institutional constraints
Visit date ranges

The defined population becomes your sampling frame. Use consistent criteria across all data

sources. Document population characteristics in your Pharma SOP documentation.

Step 2: Choose the Right Sampling Method

The choice of sampling method depends on study goals, data availability, and potential biases. Common techniques include:

1. Simple Random Sampling

Every chart in the population has an equal chance of selection. This method is statistically robust and easy to implement using software-generated random numbers.

2. Systematic Sampling

Select every “k-th” chart from a list sorted by time or patient ID. Useful for maintaining temporal representation. Ensure no patterns exist in the list that could introduce bias.

3. Stratified Sampling

Divide the population into strata (e.g., age group, gender, diagnosis), then randomly sample within each stratum. This ensures proportionate representation of key subgroups.

4. Proportional Sampling

Used in multi-center studies where samples from each site are taken in proportion to patient volume. Supports cross-site comparison and regulatory acceptability.

5. Convenience Sampling (Not Recommended)

Choosing charts that are easy to access introduces significant bias. This method should only be used for feasibility assessments—not final analysis.

In all cases, describe your strategy in the protocol, ideally aligned with stability studies in pharmaceuticals.

Step 3: Determine Optimal Sample Size

The ideal sample size depends on the following:

Primary outcome or endpoint
Effect size and variability
Confidence level (commonly 95%)
Power (commonly 80%)
Population size and expected exclusions

Use statistical software or formulas to calculate sample size. For example, when estimating proportions, the formula is:

n = (Z^2 × p × (1 - p)) / E^2
Where:
n = sample size
Z = Z-value (e.g., 1.96 for 95% confidence)
p = estimated proportion
E = margin of error

Account for potential chart ineligibility or missing data by inflating sample size by 10–20%.

Step 4: Randomization and Blinding in Abstraction

While blinding is uncommon in retrospective studies, random chart selection minimizes selection bias. Use tools like REDCap, SAS, or R to generate random samples.

Ensure abstractors are unaware of study hypothesis if possible
Avoid temporal clustering unless studying trends over time
Balance charts across treatment arms (if applicable)

Track all selections with a secure audit log, compliant with validation master plan requirements.

Step 5: Document Your Sampling Protocol

Include the following in your protocol and IRB submission:

Population eligibility criteria
Sampling method and rationale
Sample size calculation with assumptions
List of sampled charts (with de-identified IDs)
Handling of non-eligible or incomplete charts

Use this as part of your pharma regulatory requirements documentation and archiving.

Step 6: Avoid Common Sampling Pitfalls

Be cautious of these common mistakes:

Using outdated or inconsistent source data
Sampling only from one clinic or physician
Failing to account for seasonal or demographic trends
Underestimating sample size needed for subgroup analysis
Not pre-specifying replacement rules for ineligible charts

Address these in your SOP training pharma to ensure cross-functional understanding.

Step 7: Pilot Test Your Sampling Strategy

Before full abstraction begins:

Run a mini-sample of 20–30 charts
Check abstraction feasibility, data completeness, and time per chart
Refine inclusion/exclusion criteria if needed

Document learnings and revise protocol accordingly. Include this test in your study master file or chart review log.

Conclusion:

A sound sampling strategy is the foundation of credible and defensible retrospective research. By carefully defining your population, selecting appropriate sampling methods, and determining the correct sample size, you ensure that your chart review findings will be robust, reproducible, and regulatory-ready. Incorporate pilot testing, proper documentation, and adherence to validated procedures to meet both scientific and compliance goals. Sampling may be just one step—but it determines the reliability of all steps that follow.